Drugs / XL281
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01245556 | Jan 2011 → Nov 2012 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00451880 | Feb 2007 → Oct 2011 | colorectal cancer, melanoma, non-small cell lung carcinoma, thyroid gland papillary carcinoma | Exelixis | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01086267 | Jul 2010 → Aug 2011 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL281 | “A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer” NCT01086267 ↗ |
| Known as | BMS-908662 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01086267 ↗ |
| Known as | Bms-908662 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545027 ↗ |
| Known as | EXEL-2819 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545027 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL3545027 ↗2“Serine/threonine-protein kinase RAF inhibitor” CHEMBL3545027 ↗ “multiple Raf kinase inhibitor” NCT00451880 ↗ |
| Modality | Small molecule | — CHEMBL3545027 ↗ |
| Route | Oral | “Administered Orally” NCT00451880 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL3545027 ↗ |
| Target | RAF1 | “Serine/threonine-protein kinase RAF inhibitor” CHEMBL3545027 ↗ |